References
- Min H., Morony S., Sarosi I., Dunstan C. R., Capparelli C., Scully S., et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000; 192: 463–74
- Dhore C. R., Cleutjens J. P., Lutgens E., Cleutjens K. B., Geusens P. P., Kitslaar P. J., et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001; 21: 1998–2003
- Browner W. S., Lui L. Y., Cummings S. R. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001; 86: 631–7
- Jono S., Ikari Y., Shioi A., Mori K., Miki T., Hara K., et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002; 106: 1192–4
- Schoppet M., Sattler A. M., Schaefer J. R., Herzum M., Maisch B., Hofbauer L. C. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003; 88: 1024–8
- Ueland T., Jemtland R., Godang K., Kjekshus J., Hognestad A., Omland T., et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004; 44: 1970–6
- Avignon A., Sultan A., Piot C., Elaerts S., Cristol J. P., Dupuy A. M. Osteoprotegerin is associated with silent coronary artery disease in high‐risk but asymptomatic type 2 diabetic patients. Diabetes Care 2005; 28: 2176–80
- Anand D. V., Lahiri A., Lim E., Hopkins D., Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006; 47: 1850–7
- Knudsen S. T., Foss C. H., Poulsen P. L., Andersen N. H., Mogensen C. E., Rasmussen L. M. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 2003; 149: 39–42
- Rasmussen L., Tarnow L., Hansen T., Parving H., Flyvbjerg A. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol 2006; 154: 75–81
- Olesen P., Ledet T., Rasmussen L. M. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF‐alpha. Diabetologia 2005; 48: 561–8
- Andersen L., Dinesen B., Jorgensen P. N., Poulsen F., Roder M. E. Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 1993; 39: 578–82
- Simonet W. S., Lacey D. L., Dunstan C. R., Kelley M., Chang M. S., Luthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309–19
- Bucay N., Sarosi I., Dunstan C. R., Morony S., Tarpley J., Capparelli C., et al. Osteoprotegerin‐deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260–8
- Malyankar U. M., Scatena M., Suchland K. L., Yun T. J., Clark E. A., Giachelli C. M. Osteoprotegerin is an alpha vbeta 3‐induced, NF‐kappa B‐dependent survival factor for endothelial cells. J Biol Chem 2000; 275: 20959–62
- Zhang J., Fu M., Myles D., Zhu X., Du J., Cao X., et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett 2002; 521: 180–4
- Stratton I. M., Adler A. I., Neil H. A., Matthews D. R., Manley S. E., Cull C. A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000; 321: 405–12